News story

Joint MHRA and Drug Information Association training: Excellence in Pharmacovigilance

This 5-day course covers key aspects of global and European clinical pre-and-post-marketing safety regulatory requirements.

Pills

About the training

As well as providing a firm grounding on key aspects of global and European clinical pre-and-post-marketing safety regulatory requirements, the course covers updates on pharmacovigilance legislation. It also covers the latest news on the international harmonisation and standardisation activities in pharmacovigilance.

The key topics include:

  • definitions and methods in pharmacovigilance
  • regulatory aspects in pharmacovigilance and practical examples
  • diagnosis and management of adverse drug reactions
  • signal detection and signal management
  • risk management

Who should attend

The course is for professionals involved in pharmacovigilance and qualified persons for pharmacovigilance (EU QPPV) as well as those involved in:

  • clinical research, regulatory affairs, risk management
  • medical product safety assessment
  • data analysis, epidemiology, labelling
  • quality assurance, compliance, medical information

Details

Date and location

28 September to 2 October 2015

Holiday Inn Kensington Forum Hotel
London
United Kingdom
SW7 4DN

See the course outline (PDF, 884KB, 5 pages) for more information and register to book your place on the course.

Alternatively you can return the paper form by email to emea@diaglobal.org or fax +41 61 225 51 52.

CPD credits

According to the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom you are eligible for 25 CPD credits with this course.

The Swiss Association of Pharmaceutical Professionals (SwAPP) and the Swiss Society for Pharmaceutical Medicine (SGPM) have accredited this training course with 32 credits.

Published 25 August 2015